Lamivudine prophylaxis prevents hepatitis b reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non–hodgkin's B cell lymphoma
Mauro Viganò(Ospedale San Giuseppe), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), M Cappelletti(University of Milan), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori), G. Grossi(University of Milan), Paolo Corradini(Gruppo di Ricerca Geriatrica), Luca Baldini(University of Milan), Maria Grazia Rumi(University of Milan), M. Colombo(University of Milan), Maria Goldaniga(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Edoardo Borsotti
Cited by 3
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661